계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
GenEdit
About
GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
- 11 - 50
Details
- Last Funding Type
- Pre-seed
- Industries
- Biotechnology,Genetics,Pharmaceutical,Therapeutics
- Founded date
- Apr 4, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 23, 2021 | Series A | $26M | 2 | — | — | Detail |
| Jan 29, 2019 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
| Dec 11, 2018 | Seed | $8.50M | 1 | — | — | Detail |
| Aug 1, 2016 | Pre-seed | — | 1 |
Sequoia Capital
|
— | Detail |
Investments
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
|
Sequoia Capital
|
— | Series A |
|
|
— | Series A |
